Alloexposed blood donors and transfusion‐related acute lung injury: a case‐referent study

BACKGROUND: Donor white blood cell (WBC) antibodies are thought to increase the risk of transfusion‐related acute lung injury (TRALI). WBC antibodies can be present in blood products from donors who have been alloexposed. Alloexposed donors are increasingly excluded from donating plasma, but can still donate plasma‐poor products. We aimed to quantify the contribution of alloexposed donors to the occurrence of TRALI for different blood product types.

[1]  E. Beckers,et al.  Male‐only fresh‐frozen plasma for transfusion‐related acute lung injury prevention: before‐and‐after comparative cohort study , 2011, Transfusion.

[2]  H. Vrielink,et al.  Prevalence of leucocyte antibodies in the Dutch donor population , 2011, Vox sanguinis.

[3]  M. Mathru.  A solution to the problem of studying blood donor–related risk factors when patients have received multiple transfusions , 2011 .

[4]  J. Vandenbroucke,et al.  Female donors and transfusion‐related acute lung injury , 2010, Transfusion.

[5]  J. Vandenbroucke,et al.  A solution to the problem of studying blood donor–related risk factors when patients have received multiple transfusions , 2010, Transfusion.

[6]  C. Silliman,et al.  Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. , 2009, Blood reviews.

[7]  C. Hillyer,et al.  The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategy , 2009, Transfusion.

[8]  N. Soni,et al.  Ten years of hemovigilance reports of transfusion‐related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma , 2009, Transfusion.

[9]  S. Saidman,et al.  Testing only donors with a prior history of pregnancy or transfusion is a logical and cost‐effective transfusion‐related acute lung injury prevention strategy , 2008, Transfusion.

[10]  B. Keller-Stanislawski,et al.  Specificities of leucocyte alloantibodies in transfusion‐related acute lung injury and results of leucocyte antibody screening of blood donors , 2008, Vox sanguinis.

[11]  C. Chapman,et al.  How much residual plasma may cause TRALI? , 2008, Transfusion medicine.

[12]  J. G. van der Bom,et al.  The role of donor antibodies in the pathogenesis of transfusion‐related acute lung injury: a systematic review , 2008, Transfusion.

[13]  A. Leaver,et al.  Acute lung injury after ruptured abdominal aortic aneurysm repair: The effect of excluding donations from females from the production of fresh frozen plasma* , 2008, Critical care medicine.

[14]  B. M. Taleghani,et al.  Swiss Haemovigilance Data and Implementation of Measures for the Prevention of Transfusion Associated Acute Lung Injury (TRALI) , 2008, Transfusion Medicine and Hemotherapy.

[15]  M. Marques,et al.  Transfusion-related acute lung injury: past, present, and future. , 2008, American journal of clinical pathology.

[16]  J. Wallis.  Transfusion-related acute lung injury (TRALI): presentation, epidemiology and treatment , 2007, Intensive Care Medicine.

[17]  U. Sachs.  Pathophysiology of TRALI: current concepts , 2007, Intensive Care Medicine.

[18]  S. Moore,et al.  Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. , 2006, Critical care medicine.

[19]  N. Ali,et al.  Haemovigilance , 2006, Vox sanguinis.

[20]  J. Bux.  Transfusion‐related acute lung injury (TRALI): a serious adverse event of blood transfusion , 2005, Vox sanguinis.

[21]  Jürgen Neppert,et al.  Re: Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel , 2005, Transfusion.

[22]  J. Freedman,et al.  Proceedings of a consensus conference: towards an understanding of TRALI. , 2005, Transfusion medicine reviews.

[23]  Robertson Davenport,et al.  Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel , 2004, Transfusion.

[24]  P. Kopko.  Review: transfusion-related acute lung injury: pathophysiology, laboratory investigation, and donor management , 2004, Immunohematology.

[25]  R. Boulton-Jones.  The impact of screening a platelet donor panel for human leucocyte antigen antibodies to reduce the risk of transfusion‐related acute lung injury , 2003, Transfusion Medicine.

[26]  C. Silliman,et al.  Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. , 2003, Blood.

[27]  S. Dry,et al.  The pathology of transfusion-related acute lung injury. , 1999, American journal of clinical pathology.

[28]  H. Chaplin,et al.  Prevalence of HLA sensitization in female apheresis donors , 1999, Transfusion.

[29]  A. Paterson,et al.  The association of biologically active lipids with the development of transfusion‐related acute lung injury: a retrospective study , 1997, Transfusion.

[30]  W. A. Zellmer.  Toward understanding. , 1988, American journal of hospital pharmacy.

[31]  S. Moore,et al.  Diagnostic and pathogenetic considerations in transfusion‐related acute lung injury , 1985, Transfusion.

[32]  S Greenland,et al.  Concepts of interaction. , 1980, American journal of epidemiology.

[33]  R. Payne,et al.  The development and persistence of leukoagglutinins in parous women. , 1962, Blood.